Legal attitude: Art. 17 para. 1 MAR - confidential information.
The Management Board of GLG Pharma S.A. (Company, Issuer) informs that on July 13, 2018, it accepted the partial report received from the Institute of Organic Industry with its seat in Warsaw, Branch in Pszczyna (Institute) for the second stage of works covered by the agreement of 31 August 2017 on the conclusion of which The company informed in the current report ESPI No. 13/2017 (Agreement).
According to the received report, the work carried out by the Institute as part of the implementation of stage II proceeded according to the assumed research plan. Stage II of the work included an acute toxicity study. As part of this stage, studies were conducted involving a single dose administration of the GLG-805 molecule by oral and intraperitoneal rats, which allowed the assessment of acute toxicity and the determination of the maximum tolerated dose of the tested molecule.
The Management Board of the Company assessed the work covered by the partial report as performed in accordance with the terms of the Agreement, as well as in accordance with the objectives of the project for the development of targeted therapy for triple negative breast cancer (TNBC). At the request of the Institute, stage II was implemented as the first under the Agreement, and stage I provided for in the Agreement will be implemented within 2 months from the end of stage II. A change in the order of execution of the stages of the Agreement does not affect the results or deadlines for the performance of the Agreement. The goal of stage I is to determine the range of doses used for the GLG-805 (DRF-Dose Range Finding) molecule.
The Management Board of the Company will inform about the implementation of subsequent stages of the Agreement in separate current reports.
Source: company website, investor relations, current and periodic reports.